Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ameliorate renal ischemia-reperfusion injury (IRI) by modulating autophagic processes
Translational Research · 2025-03 · 277 · 27-38
DOI: 10.1016/j.trsl.2024.12.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2025-03. Verfasst von Mengmeng Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China. Hauptthemen laut MEDLINE: Reperfusion Injury, Sodium-Glucose Transporter 2 Inhibitors, Autophagy, Kidney. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Renal ischemia-reperfusion injury (IRI) is a common clinical condition that currently lacks effective treatment options. Inhibitors targeting the sodium-glucose co-transporter-2 (SGLT-2), recognized for their role in managing hyperglycemia, have demonstrated efficacy in enhancing the health outcomes for diabetic patients grappling with chronic kidney disease. Nevertheless, the precise impact of SGLT-2 inhibitors on renal ischemia-reperfusion injury (IRI) and the corresponding transcriptomic alterations remain to be elucidated. In our research, we developed a model of IRI using male C57BL/6 mice by clamping the unilateral renal artery and administering empagliflozin Transcriptomic alterations were analyzed using RNA sequencing (RNA-Seq), complemented by proteomic analysis to investigate the effects of empagliflozin. Histological assessments revealed increased renal inflammatory cell infiltration, widespread renal tubular injury, and elevated autophagosomes formation in the IRI group compared to controls. These pathological changes were significantly attenuated following empagliflozin treatment. Besides, renal function impairment can be alleviated in empagliflozin-treated group. RNA-Seq analysis identified lysosomal autophagy as a key biological process in IRI mice. Empagliflozin exerted a renoprotective effect by downregulating lysosome-associated membrane proteins, primarily LAMP1, LAMP2, and LAMP4 (CD68), through the PI3K-Akt, MAPK, and mTOR signaling pathways, thereby inhibiting autophagic processes. In conclusion, this study highlights enhanced inflammation and disrupted metabolism as hallmark transcriptomic signatures of renal. Furthermore, it demonstrates the renoprotective effects of empagliflozin in alleviating renal IRI by modulating autophagic processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
- Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
- Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China. Electronic address: jiangyh686@hospital.cqmu.edu.cn.
- Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China. Electronic address: yuanxin@cqmu.edu.cn.
Zitieren
APA
Liu, M., Yao, Y., Tan, F., Wang, J., Hu, R., Du, J., Jiang, Y., & Yuan, X. (2025). Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ameliorate renal ischemia-reperfusion injury (IRI) by modulating autophagic processes. Translational Research, 277, 27-38. https://doi.org/10.1016/j.trsl.2024.12.006
Vancouver
Liu M, Yao Y, Tan F, Wang J, Hu R, Du J, et al. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ameliorate renal ischemia-reperfusion injury (IRI) by modulating autophagic processes. Translational Research. 2025;277:27-38. doi:10.1016/j.trsl.2024.12.006
BibTeX
@article{Liu2025,
author = {Liu, Mengmeng and Yao, Yuanqing and Tan, Fangyan and Wang, Jing and Hu, Rong and Du, Jianlin and Jiang, Yonghong and Yuan, Xin},
title = {Sodium-glucose co-transporter 2 (SGLT-2) inhibitors ameliorate renal ischemia-reperfusion injury (IRI) by modulating autophagic processes},
journal = {Translational Research},
year = {2025},
volume = {277},
pages = {27--38},
doi = {10.1016/j.trsl.2024.12.006}
}
EUVIMED